[{"id":"938d3f31-19a2-4d93-b968-94fc075d0fd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03936465","created_at":"2021-01-18T19:23:12.104Z","updated_at":"2024-07-02T16:35:13.440Z","phase":"Phase 1","brief_title":"Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer","source_id_and_acronym":"NCT03936465","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • MYCN • BRD4 • BRD3","pipe":" | ","alterations":" MYCN amplification","tags":["MYC • MYCN • BRD4 • BRD3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezobresib (BMS-986158) • trotabresib (BMS-986378)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/27/2019","start_date":" 09/27/2019","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 07/16/2024","study_completion_date":" 07/16/2024","last_update_posted":"2024-03-21"}]